Evidence map›Paper›PMID 41038856›Full record

ArticleNPJ breast cancer2025

Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy.

Javier Cortes, Oleg Lipatov, Seock-Ah Im, Anthony Goncalves, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Shoichiro Ohtani, Nadia Harbeck and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Javier CortesInternational Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, and IOB Madrid, Hospital Beata Maria Ana, and Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain. jacortes@vhio.net.
Oleg LipatovRepublican Clinical Oncology Dispensary, Republic of Bashkortostan, Ufa, Russian Federation.
Seock-Ah ImSeoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Anthony GoncalvesAix Marseille University, CNRS, INSERM, Medical Oncology Department, Institut Paoli-Calmettes, CRCM, Marseille, France.
Keun Seok LeeCenter for Breast Cancer, National Cancer Center, Goyang, Republic of Korea.
Peter SchmidCentre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK.
Kenji TamuraNational Cancer Center Hospital, Tokyo, Japan.
Laura TestaInstituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade do Estado do São Paulo, São Paulo, Brazil.
Shoichiro OhtaniHiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Nadia HarbeckBreast Center, Department of Obstetrics and Gynecology and CCC Munich, Ludwig-Maximilians University, Munich, Germany.
Sherene LoiDivision of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Roberto SalgadoDivision of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Vassiliki KarantzaMerck & Co., Inc., Rahway, NJ, USA.
Jaime MejiaMerck & Co., Inc., Rahway, NJ, USA.
Razvan CristescuMerck & Co., Inc., Rahway, NJ, USA.
Andrey LobodaMerck & Co., Inc., Rahway, NJ, USA.
Michael NebozhynMerck & Co., Inc., Rahway, NJ, USA.
Petar JelinicMerck & Co., Inc., Rahway, NJ, USA.
Lingkang HuangMerck & Co., Inc., Rahway, NJ, USA.
Eric P WinerYale Cancer Center, New Haven, CT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the randomized, phase 3 KEYNOTE-119 study, overall survival (OS) was not significantly improved with pembrolizumab 200 mg Q3W versus investigator's choice of chemotherapy in participants with previously treated metastatic TNBC. In this exploratory analysis, we evaluated associations of tumor-infiltrating lymphocytes (TILs), T-cell‒inflamed gene expression profile (Tcell

Identifiers

PMID41038856
PMCPMC12491503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.